{
  "drugs": {
    "warfarin": {
      "name": "Warfarin",
      "category": "Anticoagulant",
      "interactions": [
        {
          "gene": "CYP2C9",
          "rsid": "rs1799853",
          "risk_allele": "T",
          "normal_allele": "C",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use standard warfarin dosing (5-7.5 mg/day)." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate Metabolizer (*1/*2)", "recommendation": "Consider 20-30% dose reduction. Monitor INR closely during initiation." },
            "1/1": { "level": "HIGH", "phenotype": "Poor Metabolizer (*2/*2)", "recommendation": "Reduce dose by 40-50%. High bleeding risk—frequent INR monitoring required." }
          },
          "evidence": ["CPIC Guideline (2017)", "PharmGKB:PA166104949", "FDA Label"]
        },
        {
          "gene": "CYP2C9",
          "rsid": "rs1057910",
          "risk_allele": "C",
          "normal_allele": "A",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use standard warfarin dosing." },
            "0/1": { "level": "HIGH", "phenotype": "Intermediate Metabolizer (*1/*3)", "recommendation": "Reduce dose by 30-40%. CYP2C9*3 has greater effect than *2." },
            "1/1": { "level": "CRITICAL", "phenotype": "Poor Metabolizer (*3/*3)", "recommendation": "Reduce dose by 50-70%. Very high bleeding risk. Consider alternative anticoagulant." }
          },
          "evidence": ["CPIC Guideline (2017)", "PharmGKB:PA166104949", "PMID:18305455"]
        },
        {
          "gene": "VKORC1",
          "rsid": "rs9923231",
          "risk_allele": "T",
          "normal_allele": "C",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal VKORC1 Expression", "recommendation": "Use standard warfarin dosing." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate VKORC1 Expression", "recommendation": "Consider 25-30% lower starting dose." },
            "1/1": { "level": "HIGH", "phenotype": "Low VKORC1 Expression", "recommendation": "May require 40-50% lower dose. Increased warfarin sensitivity." }
          },
          "evidence": ["CPIC Guideline (2017)", "PharmGKB:PA166104956", "PMID:15930419"]
        }
      ]
    },
    "clopidogrel": {
      "name": "Clopidogrel",
      "category": "Antiplatelet",
      "interactions": [
        {
          "gene": "CYP2C19",
          "rsid": "rs4244285",
          "risk_allele": "A",
          "normal_allele": "G",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use standard clopidogrel dosing (75 mg/day)." },
            "0/1": { "level": "HIGH", "phenotype": "Intermediate Metabolizer (*1/*2)", "recommendation": "Reduced platelet inhibition. Consider alternative antiplatelet (prasugrel/ticagrelor)." },
            "1/1": { "level": "CRITICAL", "phenotype": "Poor Metabolizer (*2/*2)", "recommendation": "Clopidogrel likely ineffective. Switch to prasugrel or ticagrelor. Boxed Warning applies." }
          },
          "evidence": ["CPIC Guideline (2013, updated 2022)", "PharmGKB:PA166104948", "FDA Boxed Warning"]
        },
        {
          "gene": "CYP2C19",
          "rsid": "rs4986893",
          "risk_allele": "A",
          "normal_allele": "G",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use standard clopidogrel dosing." },
            "0/1": { "level": "HIGH", "phenotype": "Intermediate Metabolizer (*1/*3)", "recommendation": "CYP2C19*3 is a no-function allele. Consider alternative antiplatelet." },
            "1/1": { "level": "CRITICAL", "phenotype": "Poor Metabolizer (*3/*3)", "recommendation": "Clopidogrel ineffective. Use prasugrel or ticagrelor." }
          },
          "evidence": ["CPIC Guideline (2022)", "PharmGKB:PA166104948"]
        }
      ]
    },
    "codeine": {
      "name": "Codeine",
      "category": "Opioid Analgesic",
      "interactions": [
        {
          "gene": "CYP2D6",
          "rsid": "rs3892097",
          "risk_allele": "A",
          "normal_allele": "G",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use codeine per standard guidelines." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate Metabolizer (*1/*4)", "recommendation": "Reduced morphine formation. Monitor for inadequate pain relief." },
            "1/1": { "level": "HIGH", "phenotype": "Poor Metabolizer (*4/*4)", "recommendation": "Codeine is ineffective (no conversion to morphine). Use alternative analgesic (non-tramadol opioid or non-opioid)." }
          },
          "evidence": ["CPIC Guideline (2014, updated 2020)", "PharmGKB:PA166104996", "FDA Safety Communication"]
        },
        {
          "gene": "CYP2D6",
          "rsid": "rs5030655",
          "risk_allele": "T",
          "normal_allele": "A",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Metabolizer", "recommendation": "Use codeine per standard guidelines." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate Metabolizer (*1/*6)", "recommendation": "Reduced CYP2D6 activity. May need dose adjustment or alternative." },
            "1/1": { "level": "HIGH", "phenotype": "Poor Metabolizer (*6/*6)", "recommendation": "Codeine is ineffective. Use alternative analgesic." }
          },
          "evidence": ["CPIC Guideline (2020)", "PharmGKB:PA166104996"]
        }
      ]
    },
    "simvastatin": {
      "name": "Simvastatin",
      "category": "Statin (HMG-CoA Reductase Inhibitor)",
      "interactions": [
        {
          "gene": "SLCO1B1",
          "rsid": "rs4149056",
          "risk_allele": "C",
          "normal_allele": "T",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal Transporter Function", "recommendation": "Use standard simvastatin dosing." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate Transporter Function", "recommendation": "Avoid simvastatin >20 mg/day. Monitor for myopathy symptoms." },
            "1/1": { "level": "HIGH", "phenotype": "Poor Transporter Function", "recommendation": "Avoid simvastatin or use ≤20 mg/day. High myopathy risk (OR 16.9). Consider pravastatin or rosuvastatin." }
          },
          "evidence": ["CPIC Guideline (2014)", "PharmGKB:PA166105005", "PMID:18650507"]
        }
      ]
    },
    "fluorouracil": {
      "name": "Fluorouracil (5-FU)",
      "category": "Antineoplastic",
      "interactions": [
        {
          "gene": "DPYD",
          "rsid": "rs3918290",
          "risk_allele": "T",
          "normal_allele": "C",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal DPD Activity", "recommendation": "Use standard fluorouracil dosing." },
            "0/1": { "level": "CRITICAL", "phenotype": "Intermediate DPD Activity (*1/*2A)", "recommendation": "Reduce dose by 50%. Life-threatening toxicity risk without dose reduction." },
            "1/1": { "level": "CRITICAL", "phenotype": "DPD Deficient (*2A/*2A)", "recommendation": "CONTRAINDICATED. Complete DPD deficiency—fatal toxicity risk. Use alternative regimen." }
          },
          "evidence": ["CPIC Guideline (2017)", "PharmGKB:PA166122686", "EMA Recommendation"]
        }
      ]
    },
    "azathioprine": {
      "name": "Azathioprine",
      "category": "Immunosuppressant",
      "interactions": [
        {
          "gene": "TPMT",
          "rsid": "rs1800460",
          "risk_allele": "A",
          "normal_allele": "G",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal TPMT Activity", "recommendation": "Use standard azathioprine dosing (2-3 mg/kg/day)." },
            "0/1": { "level": "HIGH", "phenotype": "Intermediate TPMT Activity (*1/*3B)", "recommendation": "Reduce dose by 30-50%. Monitor CBC weekly during initiation." },
            "1/1": { "level": "CRITICAL", "phenotype": "TPMT Deficient (*3B/*3B)", "recommendation": "Reduce dose by 90% or use alternative. Risk of fatal myelosuppression." }
          },
          "evidence": ["CPIC Guideline (2011, updated 2018)", "PharmGKB:PA166104945"]
        },
        {
          "gene": "TPMT",
          "rsid": "rs1142345",
          "risk_allele": "C",
          "normal_allele": "T",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal TPMT Activity", "recommendation": "Use standard azathioprine dosing." },
            "0/1": { "level": "HIGH", "phenotype": "Intermediate TPMT Activity (*1/*3C)", "recommendation": "Reduce dose by 30-50%. Monitor for myelotoxicity." },
            "1/1": { "level": "CRITICAL", "phenotype": "TPMT Deficient (*3C/*3C)", "recommendation": "Reduce dose by 90% or use alternative agent." }
          },
          "evidence": ["CPIC Guideline (2018)", "PharmGKB:PA166104945"]
        }
      ]
    },
    "irinotecan": {
      "name": "Irinotecan",
      "category": "Antineoplastic",
      "interactions": [
        {
          "gene": "UGT1A1",
          "rsid": "rs8175347",
          "risk_allele": "TA7",
          "normal_allele": "TA6",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "Normal UGT1A1 Activity (*1/*1)", "recommendation": "Use standard irinotecan dosing." },
            "0/1": { "level": "MODERATE", "phenotype": "Intermediate UGT1A1 Activity (*1/*28)", "recommendation": "Monitor for neutropenia and diarrhea. Consider dose reduction if toxicity occurs." },
            "1/1": { "level": "HIGH", "phenotype": "Poor UGT1A1 Activity (*28/*28)", "recommendation": "Reduce initial dose by at least 30%. High risk of severe neutropenia." }
          },
          "evidence": ["CPIC Guideline (2019)", "PharmGKB:PA166104951", "FDA Label"]
        }
      ]
    },
    "tacrolimus": {
      "name": "Tacrolimus",
      "category": "Immunosuppressant",
      "interactions": [
        {
          "gene": "CYP3A5",
          "rsid": "rs776746",
          "risk_allele": "C",
          "normal_allele": "T",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "CYP3A5 Non-Expressor (*3/*3)", "recommendation": "Use standard tacrolimus dosing. Most patients are non-expressors." },
            "0/1": { "level": "MODERATE", "phenotype": "CYP3A5 Intermediate Expressor (*1/*3)", "recommendation": "May require 1.5-2x higher dose to achieve target trough levels." },
            "1/1": { "level": "HIGH", "phenotype": "CYP3A5 Expressor (*1/*1)", "recommendation": "Likely requires 2-3x higher starting dose. Rapid metabolism—monitor trough levels." }
          },
          "evidence": ["CPIC Guideline (2015)", "PharmGKB:PA166124619"]
        }
      ]
    },
    "abacavir": {
      "name": "Abacavir",
      "category": "Antiretroviral (NRTI)",
      "interactions": [
        {
          "gene": "HLA-B",
          "rsid": "rs2395029",
          "risk_allele": "T",
          "normal_allele": "G",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "HLA-B*57:01 Negative", "recommendation": "Use abacavir per standard guidelines." },
            "0/1": { "level": "CRITICAL", "phenotype": "HLA-B*57:01 Carrier", "recommendation": "CONTRAINDICATED. Do NOT prescribe abacavir. Risk of fatal hypersensitivity reaction." },
            "1/1": { "level": "CRITICAL", "phenotype": "HLA-B*57:01 Homozygous", "recommendation": "CONTRAINDICATED. Do NOT prescribe abacavir." }
          },
          "evidence": ["CPIC Guideline (2014)", "PharmGKB:PA166104997", "FDA Boxed Warning"]
        }
      ]
    },
    "carbamazepine": {
      "name": "Carbamazepine",
      "category": "Anticonvulsant",
      "interactions": [
        {
          "gene": "HLA-B",
          "rsid": "rs3909184",
          "risk_allele": "C",
          "normal_allele": "T",
          "phenotypes": {
            "0/0": { "level": "NORMAL", "phenotype": "HLA-B*15:02 Negative", "recommendation": "Use carbamazepine per standard guidelines." },
            "0/1": { "level": "CRITICAL", "phenotype": "HLA-B*15:02 Carrier", "recommendation": "CONTRAINDICATED in patients of Southeast Asian descent. Risk of Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis." },
            "1/1": { "level": "CRITICAL", "phenotype": "HLA-B*15:02 Homozygous", "recommendation": "CONTRAINDICATED. Do NOT prescribe carbamazepine." }
          },
          "evidence": ["CPIC Guideline (2013)", "PharmGKB:PA166104943", "FDA Warning"]
        }
      ]
    }
  }
}
